Here's the HR data across the major GLP-1 RA trials for reference:

These are means, and individual variation is substantial (standard deviations of ~5-8 bpm). The OP's 14 bpm increase is approximately 1.5-2 standard deviations above the mean, so it's an above-average response but within the observed distribution.

Notably, in none of these trials did the HR increase translate into excess cardiovascular events. The HR increase appears to be a pharmacological effect without adverse clinical consequences in the studied populations.

I'm glad this thread exists because I noticed the same thing on tirzepatide. My resting HR went from 72 to 84 over 3 months. My Apple Watch actually flagged me with an "elevated heart rate" notification one evening when I was sitting on the couch at 94 bpm. That spooked me.

My doctor ran an ECG which was completely normal. She explained that the heart is beating faster but there's no arrhythmia or structural issue. She also mentioned that as I lose weight and become more fit, the HR should gradually come back down. Has anyone experienced that — the HR normalizing over time?

I'm 11 months in on semaglutide and my HR has come down somewhat from the peak. It went from 66 → 80 in the first 4 months, then gradually settled to about 76 by month 8. I also started cardio exercise (30 min cycling 4x/week) around month 5, which probably helped with parasympathetic tone. So yes, there does seem to be some adaptation over time.

The normalization pattern described above is consistent with what I see in practice. The initial HR increase is most pronounced during the dose titration phase and the first 3-4 months at maintenance dose. After that, partial adaptation occurs in most patients.

Regular aerobic exercise is the best non-pharmacological intervention for elevated resting HR, as it enhances vagal tone and counteracts the sympathetic activation from GLP-1 RAs. Even modest cardio (walking 30 min/day) has been shown to reduce resting HR by 3-5 bpm over 8-12 weeks.

Bottom line for everyone: monitor, stay aware, report symptoms, but don't let a modest HR increase derail a therapy that's providing substantial metabolic and cardiovascular benefit. The risk-benefit ratio strongly favors continuing GLP-1 RA therapy.